Related Experiment Video

Updated: Nov 24, 2025

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.1K

The critical function of miR-1323/Il6 axis in children with Mycoplasma pneumoniae pneumonia

Linlin Yin1, Yajun Ma2, Wenlong Wang1

  • 1Cangzhou Central Hospital, Department of Clinical Laboratory, Hebei, China.

Jornal De Pediatria
|December 21, 2020
PubMed
Abstract

Insights

MicroRNA-1323 (miR-1323) plays a crucial role in Mycoplasma pneumoniae pneumonia (MPP) by inhibiting interleukin-6 (IL-6) expression. Reduced miR-1323 levels in MPP patients lead to increased IL-6 and inflammation.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pediatric Respiratory Medicine

Background:

  • Mycoplasma pneumoniae pneumonia (MPP) is a prevalent pediatric respiratory illness.
  • Immune response modulators like TNF-α, IL-17, and IL-6 are implicated in MPP pathogenesis.
  • MicroRNAs (miRNAs) are key regulators of immune cell development and disease pathways.

Purpose of the Study:

  • To investigate the role of differentially expressed miRNAs in pediatric MPP.
  • To identify specific miRNAs and their target genes involved in MPP pathogenesis.
  • To elucidate the regulatory mechanism of miR-1323 in MPP and associated inflammation.

Main Methods:

  • Blood samples were collected from children with MPP and healthy controls.
  • miRNA expression profiling was performed using microarray analysis.
  • Quantitative real-time PCR (qRT-PCR) was used to validate miRNA and mRNA expression levels.
  • In vitro experiments using THP-1 cell line were conducted to assess miR-1323's effect on IL-6 expression.

Main Results:

  • Twenty-three differentially expressed miRNAs were identified in MPP patients, with 15 upregulated and 8 downregulated.
  • A significant decrease in miR-1323 levels was observed in MPP patients compared to controls.
  • Elevated IL-6 and IL-17a mRNA levels were found in MPP patients with pleural effusion.
  • IL-6 expression showed a negative correlation with miR-1323 levels.
  • miR-1323 directly targets and inhibits IL-6 mRNA expression.

Conclusions:

  • miR-1323 acts as a negative regulator of IL-6 expression in the context of MPP.
  • MPP pathogenesis involves the suppression of miR-1323 in macrophages, leading to IL-6 overexpression and heightened inflammation.
  • These findings highlight miR-1323 as a potential therapeutic target for modulating inflammation in MPP.
Keywords:
Il6MPPMacrophageMycoplasma pneumoniamiR-1323

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

635
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.3K

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.9K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
626
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
509
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
593
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.7K
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
529